

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2021

		For the year ended 31 December 2021	For the period from Establishment Date to 31 December 2020
	Note	QR	QR
OPERATING ACTIVITIES			
Profit before tax for the year/period		134,463,958	152,364,486
Adjustments for:			
Depreciation of property, plant and equipment	11	111,194,633	105,981,992
Depreciation of right-of-use assets	12	13,311,193	21,217,380
Amortization of intangible assets	13	1,798,041	1,362,976
Provision for employees' end of service benefits	25	4,033,224	3,922,656
Impairment loss allowance on trade receivables	17	89,935	721,872
(Gain)/loss on disposal of property, plant and equipment	6	(25,734)	123,392
Fair value gain on financial investments at fair value through profit or loss		(10,829,791)	-
Gain arising from change in fair value of biological assets	15	(52,470,576)	(34,808,880)
Cost of slaughtered animals disposed and transfer	15	12,014,712	9,368,921
Loss from death of livestock	15	8,875,480	7,609,277
Interest on lease liabilities	22	2,052,729	4,218,923
Finance cost		34,350,654	37,467,915
Operating cash flow before movement in working capital		258,858,458	309,550,910
Changes in:			
Inventories		28,808,994	(95,716,578)
Due from related parties		(783,393)	8,553,854
Trade and other debit balances		(29,262,625)	57,609,584
Due to related parties		9,824,157	(294,477)
Trade and other credit balances		(17,682,763)	62,780,955
Cash generated from operating activities		249,762,828	342,484,248
Employees' end of service benefit paid	25	(1,107,017)	(1,374,106)
Finance cost paid		(33,512,947)	(45,685,576)
Interest on lease liabilities paid		(2,052,729)	(4,218,923)
Income tax paid		(380,431)	(35,464)
Net cash generated from operating activities		212,709,704	291,170,179
INVESTING ACTIVITIES			
Purchase of property, plant and equipment (i)	11	(217,147,551)	(218,324,128)
Proceeds from disposal of property, plant and equipment		31,901	20,381
Purchase of intangible assets	13	(1,919,997)	(650,305)
Acquisition of financial investments at fair value through profit or loss		(133,230,227)	-
Net movement in biological assets		19,918,713	(1,880,079)
Net cash used in investing activities		(332,347,161)	(220,834,131)
FINANCING ACTIVITIES			
Net proceeds from Initial Public Offering (IPO)		-	1,425,750,000
Net movement in borrowings		244,934,488	(1,413,974,404)
Principal elements of lease payments		(12,182,458)	(21,310,988)
Dividend paid		(95,965,184)	(32,014,413)
Net movement in restricted cash		(30,838,254)	6,778,402
Net cash generated from/(used in) financing activities		105,948,592	(34,771,403)
Net (decrease)/increase in cash and cash equivalents		(13,688,865)	35,564,645
Cash and cash equivalents at beginning of the year/period		(38,935,906)	(74,500,551)
Cash and cash equivalents at the end of the year/period	18	(52,624,771)	(38,935,906)

(i) An amount of QR 278,872 has been excluded from the purchase of property, plant and equipment for the cash flow statement as it represents the finance cost capitalized during the year.

The attached notes from 1 to 37 are an integral part of these consolidated financial statements.